Risk of MGUS in relatives of multiple myeloma cases by clinical and tumor characteristics

被引:0
|
作者
Alyssa I. Clay-Gilmour
Shaji Kumar
S. Vincent Rajkumar
Abdul Rishi
Robert A. Kyle
Jerry A. Katzmann
David L. Murray
Aaron D. Norman
Alexandra J. Greenberg
Dirk R Larson
Megan M. O’Byrne
Susan L. Slager
Celine M. Vachon
机构
[1] Mayo Clinic,Department of Health Sciences Research
[2] Mayo Clinic,Division of Hematology
[3] Mercy Hospital,Department of Internal Medicine
[4] Mayo Clinic,Department of Laboratory Medicine and Pathology
来源
Leukemia | 2019年 / 33卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
We and others have shown increased risk of monoclonal gammopathy of undetermined significance (MGUS) in first-degree relatives of patients with multiple myeloma (MM). Whether familial risk of MGUS differs by the MM proband’s age at onset, tumor or clinical characteristics is unknown. MM and smoldering MM (SMM) cases (N = 430) were recruited from the Mayo Clinic in Rochester, Minnesota between 2005–2015. First-degree relatives over age 40 provided serum samples for evaluation of MGUS (N = 1179). Age and sex specific rates of MGUS among first-degree relatives were compared to a population-based sample. Cytogenetic subtypes were classified by Fluorescence in situ hybridization. MGUS was detected in 75 first-degree relatives for an age- and sex- adjusted prevalence of 5.8% (95% CI: 4.5–7.2). Prevalence of MGUS in first-degree relatives was 2.4 fold (95% CI: 1.9–2.9) greater than expected rates. Familial risk did not differ by proband’s age at diagnosis, gender, isotype, IgH translocation, or trisomy. This study confirms first-degree relatives of MM cases have a significantly higher risk of MGUS compared to the general population, regardless of age, gender, or tumor characteristics. In selected situations, such as multiple affected first-degree relatives, screening of first-degree relatives of MM cases could be considered for follow-up and prevention strategies.
引用
收藏
页码:499 / 507
页数:8
相关论文
共 50 条
  • [1] Risk of MGUS in relatives of multiple myeloma cases by clinical and tumor characteristics
    Clay-Gilmour, Alyssa I.
    Kumar, Shaji
    Rajkumar, S. Vincent
    Rishi, Abdul
    Kyle, Robert A.
    Katzmann, Jerry A.
    Murray, David L.
    Norman, Aaron D.
    Greenberg, Alexandra J.
    Larson, Dirk R.
    O'Byrne, Megan M.
    Slager, Susan L.
    Vachon, Celine M.
    LEUKEMIA, 2019, 33 (02) : 499 - 507
  • [2] Rheumatologic diseases impact the risk of progression of MGUS to overt multiple myeloma
    Steiner, Normann
    Goebel, Georg
    Michaeler, Daniela
    Platz, Anna-Luise
    Prokop, Wolfgang
    Wolf, Anna Maria
    Wolf, Dominik
    Duftner, Christina
    Gunsilius, Eberhard
    BLOOD ADVANCES, 2021, 5 (06) : 1746 - 1754
  • [3] A gene signature can predict risk of MGUS progressing to multiple myeloma
    Sun, Fumou
    Cheng, Yan
    Ying, Jun
    Mery, David
    Al Hadidi, Samer
    Wanchai, Visanu
    Siegel, Eric R.
    Xu, Hongwei
    Gai, Dongzheng
    Ashby, Timothy Cody
    Bailey, Clyde
    Chen, Jin-Ran
    Schinke, Carolina
    Thanendrarajan, Sharmilan
    Zangari, Maurizio
    Janz, Siegfried
    Barlogie, Bart
    Van Rhee, Frits
    Tricot, Guido
    Shaughnessy Jr, John D.
    Zhan, Fenghuang
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2023, 16 (01)
  • [4] Polyclonal Gamma Globulin Suppression and Risk Of MGUS Progression Into Multiple Myeloma
    Sheqwara, Jawad Z.
    Alhyari, Mohammad
    Keating, Shannon
    Kuriakose, Philip
    BLOOD, 2013, 122 (21)
  • [5] A gene signature can predict risk of MGUS progressing to multiple myeloma
    Fumou Sun
    Yan Cheng
    Jun Ying
    David Mery
    Samer Al Hadidi
    Visanu Wanchai
    Eric R. Siegel
    Hongwei Xu
    Dongzheng Gai
    Timothy Cody Ashby
    Clyde Bailey
    Jin-Ran Chen
    Carolina Schinke
    Sharmilan Thanendrarajan
    Maurizio Zangari
    Siegfried Janz
    Bart Barlogie
    Frits Van Rhee
    Guido Tricot
    John D. Shaughnessy
    Fenghuang Zhan
    Journal of Hematology & Oncology, 16
  • [6] Increased prevalence of light chain monoclonal gammopathy of undetermined significance (MGUS) in first-degree relatives of individuals with multiple myeloma or MGUS
    Greenberg, Alexandra J.
    Rajkumar, S. Vincent
    Larson, Dirk R.
    Dispenzieri, Angela
    Therneau, Terry M.
    Colby, Colin L.
    Phelps, Tara K.
    Kumar, Shaji K.
    Katzmann, Jerry A.
    Kyle, Robert A.
    Slager, Susan L.
    Vachon, Celine M.
    CANCER RESEARCH, 2012, 72
  • [7] Molecular Pathogenesis of MGUS and Multiple Myeloma
    Kuehl, W. M.
    Demchenko, Y.
    Glebov, O.
    Zingone, A.
    Staudt, L.
    Brents, L.
    Weiss, B.
    Barlogie, B.
    Shaughnessy, J.
    Bergsagel, P. L.
    CLINICAL LYMPHOMA & MYELOMA, 2009, 9 : S149 - S149
  • [8] NEUTROPHILS ARE IMPAIRED IN MULTIPLE MYELOMA BUT NOT IN MGUS
    Romano, A.
    Parrinello, N.
    La Cava, P.
    Giallongo, C.
    Tibullo, D.
    Chiarenza, A.
    Conticello, C.
    Cavalli, M.
    Palumbo, G.
    Di Raimondo, F.
    HAEMATOLOGICA, 2013, 98 : 316 - 317
  • [9] Molecular Pathogenesis of MGUS and Multiple Myeloma
    Kuehl, W. M.
    Demchenko, Y.
    Glebov, O.
    Zingone, A.
    Staudt, L.
    Brents, L.
    Weiss, B.
    Barlogie, B.
    Shaughnessy, J.
    Bergsagel, L.
    CLINICAL LYMPHOMA & MYELOMA, 2009, 9 : S11 - S11
  • [10] Hormone Replacement Therapy and Risk of Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance (MGUS) and MGUS Progression in the UK Clinical Practice Research Datalink
    Bradley, Marie C.
    McShane, Charlene
    Hughes, Carmel M.
    Landgren, Ola
    Murray, Liam
    Anderson, Lesley A.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2017, 26 : 176 - 176